What's Behind Array Biopharma Inc.'s 31% Rally in August?
Shares of Array Biopharma Inc. (NASDAQ: ARRY), a biopharmaceutical company developing new cancer therapies, gained 30.5% in August, according to data from S&P Global Market Intelligence. More details from new drug candidates that could become this company's first approved products gave the stock some lift.
Array Biopharma is definitely on to something with its lead candidates as a treatment for certain melanoma patients, but an extremely complex late-stage clinical trial program underway makes it difficult to measure odds of success for its lead candidates, binimetinib and encorafenib.
Image source: Getty Images.
Source: Fool.com
